BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER – Trademark Portfolio
Entity Type: 99
BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 25 (Clothing) across 5 Nice Classification classes. The owner is based in LONDON.
42-47 MINORIES
5TH FLOOR, IBEX HOUSE
LONDON EC3N 1DY , GB
Showing of trademarks Trademarks
Trademark Classifications
BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Education; providing of training; entertainment; sporting and cultural activities
Insurance; financial affairs; monetary affairs; real estate affairs
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER have?
BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER has 1 U.S. trademark filed with the USPTO.
What trademark classes does BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER file in?
BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER files trademarks across 5 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 25 (Clothing), Class 41 (Education & Entertainment), Class 36 (Insurance & Financial), Class 16 (Paper Goods). Class 35 covers advertising; business management; business administration; office functions.
What is BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER's trademark registration success rate?
BREAST CANCER CAMPAIGN AND BREAKTHROUGH BREAST CANCER has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.